The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone

BACKGROUND: The standard of care for metastatic gastric cancer (MGC) is systemic chemotherapy which leads to a median survival of 6-15 months. Survival beyond 3 years is rare. For selected groups of patients with limited MGC, retrospective studies have shown improved overall survival following gastr...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Kerkar, Sid P, Kemp, Clinton D, Duffy, Austin, Kammula, Udai S, Schrump, David S, Kwong, King F, Quezado, Martha, Goldspiel, Barry R, Venkatesan, Aradhana, Berger, Ann, Walker, Melissa, Toomey, Mary Ann, Steinberg, Seth M, Giaccone, Guiseppe, Rosenberg, Steven A, Avital, Itzhak
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2009
Teme:
Study protocol
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2803175/
https://ncbi.nlm.nih.gov/pubmed/20030854
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1745-6215-10-121
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki